Summit Therapeutics Gains on $2 Billion AstraZeneca Investment
AstraZeneca is investing $2 billion in Summit Therapeutics, acquiring a potential 12% stake. The partnership focuses on developing cancer drugs, including ivonescimab. Investors are closely watching upcoming FDA regulatory decisions that could impact the collaboration and Summit's market position.
ET Markets·5h ago



